Skip to main content
. 2022 Feb 12;77:103872. doi: 10.1016/j.ebiom.2022.103872

Figure 1.

Figure1

Solid tumor cell lines are less responsive to the EZH2 inhibitor GSK126. (a) Cell proliferation of B16F10, Huh7 and SMMC7721 cells in GSK126 (10-20 μM) treatment monitored by IncuCyte S3. Mean ± SEM is shown (n = 6). (b) Wound-healing assay showing the effect of GSK126 (10 μM) treatment on the migration ability of B16F10 cell lines. Mean ± SEM is shown (n = 3). Scale bars are marked in individual images. (c, d) The apoptosis rate of B16F10 cells in the presence of GSK126 (10, 13, 15 μM) was validated by flow cytometry (c) and Annexin V staining assay (d). Scale bars are marked in individual images. Mean ± SEM is shown (n = 3). One-way ANOVA with Tukey multiple comparison posttest (a, c, d) and two-tailed unpaired Student t test (b) were used to evaluate statistical significance (*P < 0.05, **P < 0.001, ***P < 0.0001). ns, nonsignificant.